ASCO GI2024｜亮点提前看，一文速览国外专家重磅研究！

2024年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于当地时间1月18日-20日召开。ASCO GI是消化系统肿瘤领域的学术盛会，会议将展示该领域最具创新性的科学进展，并探讨消化系统肿瘤未来的治疗方向。医脉通将国外专家的口头报告和快速口头摘要研究整理如下，让我们先睹为快！

 

Oral Abstract Session

口头报告专场

 

结直肠癌

 

01

摘要号：5

标题：Effect of laparoscopy-assisted vs open surgery on 3-year disease-free survival in patients with low rectal cancer: The LASRE randomized clinical trial.

报告人：Van K. Morris, MD

单位：The University of Texas MD Anderson Cancer Center

 

02

摘要号：6

标题：Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.

报告人：Hiroki Yukami, MD

单位：Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University

 

03

摘要号：7

标题：SKYSCRAPER-08: A phase III, randomized, double-Organ-preservation in rectal cancer: What is at risk when offering watch and wait for a clinical complete response? Data from 2 international registries in rectal cancer.

报告人：Laura Melina Fernandez, MD

单位：Massachusetts General Hospital

 

食管胃癌

 

01

摘要号：LBA246

标题：Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.

报告人：Yelena Y. Janjigian, MD

单位：Memorial Sloan Kettering Cancer Center

 

02

摘要号：247

标题：Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.

报告人：Salah-Eddin Al-Batran, MD

单位：Krankenhaus Nordwest, UCT-University Cancer Center and Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

 

肝胆胰肿瘤

 

01

摘要号：LBA246

标题：EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

报告人：Yelena Y. Janjigian, MD

单位：Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine

 

神经内分泌肿瘤

 

01

摘要号：LBA588

标题：[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

报告人：Simron Singh, MD, MPH

单位：Division of Medical Oncology, Sunnybrook Odette Cancer Center, University of Toronto

 

Rapid Oral Abstract Session

快速口头摘要专场

 

结直肠癌

 

01

摘要号：9

标题：Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

报告人：Pashtoon Murtaza Kasi, MD, MSc

单位：Weill Cornell Medicine, Englander Institute of Precision Medicine, NewYork-Presbyterian Hospital

 

02

摘要号：10

标题：Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.

报告人：Dominik Paul Modest, MD

单位：Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin

 

03

摘要号：11

标题：Peritoneal lavage cytology in patients with curative resection for stage II and III colorectal cancer: A multi-institutional prospective study.

报告人：Hirotoshi Kobayashi, MD, PhD

单位：Teikyo University Hospital Mizonokuchi

 

04

摘要号：12

标题：Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study.

报告人：Jeanne Tie, MD

单位：Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research

 

05

摘要号：13

标题：Refining first-line treatment decision in RAS wildtype (RAS‑WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

报告人：Julian Walter Holch, MD

单位：Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich and German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ)

 

食管胃癌

 

01

摘要号：LBA248

标题：A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study).

报告人：Anant Ramaswamy, DM

单位：Tata Memorial Hospital (HBNI)

 

02

摘要号：249

标题：A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial).

报告人：Hiroya Takeuchi, MD

单位：Department of Surgery, Hamamatsu University School of Medicine

 

03

摘要号：250

标题：First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.

报告人：Manish A. Shah, MD

单位：Weill Cornell Medical College

 

04

摘要号：251

标题：A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.

报告人：Ian Chau, MD

单位：The Royal Marsden NHS Foundation Trust

 

05

摘要号：252

标题：Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.

报告人：Ken Kato, MD, PhD

单位：National Cancer Center Hospital

 

肝胆胰肿瘤

 

01

摘要号：433

标题：Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial.

报告人：Bas Groot Koerkamp, MD, PhD

单位：Department of Surgery, Erasmus MC Cancer Institute

 

02

摘要号：435

标题：Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).

报告人：Anthony B. El-Khoueiry, MD

单位：USC Norris Comprehensive Cancer Center

 

03

摘要号：605

标题：Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114).

报告人：Klara Dorman, MD

单位：Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich and German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ)

 

神经内分泌肿瘤

 

01

摘要号：589

标题：NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).

报告人：Lorraine A. Chantrill, PhD

单位：Wollongong Hospital, NSW

 

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~